$1.320
-0.048 (-3.65%)收盤時
OCGN 資訊
OCGN 事件
Ocugen's OCU410 Receives FDA RMAT Designation
Ocugen announced that the FDA has granted RMAT designation to Ocugen's investigational product OCU410 for the treatment of geographic atrophy, secondary to dry age-related macular degeneration.
Ocugen Signs License Agreement for OCU400 with Roots Pharmaceutical
Ocugen announced the signing of a binding term sheet to negotiate and enter into a license agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for Retinitis Pigmentosa, in the Middle East and North Africa region. Pursuant to the term sheet, under the license agreement, Ocugen is expected to receive upfront license fees and near-term development milestone payments totaling up to $4M. The company would be entitled to sales milestone payments up to $255M, in addition to a 22% royalty on net sales of OCU400 generated by Ocugen's partner. Additionally, Ocugen would manufacture commercial supply of OCU400 under the terms of a related supply agreement. Additional details will be available once the definitive agreement between the parties is executed, which is expected to occur within the next 90 days. Ocugen continues to advance OCU400 through its Phase 3 liMeliGhT clinical development with a topline readout expected in Q1 2027 and BLA submission to follow.
Liquid Option Names See Borrow Rate Increases
Latest data shows the largest indicative borrow rate increases among liquid option names include: Yellowstone Midco Holdings Ii, Llc (YSS) 18.35% +1.98, Vivopower Plc (VIVO) 15.14% +1.19, New Fortress Energy (NFE) 19.86% +0.95, Merlin Inc (MRLN) 38.55% +0.67, WhiteFiber Inc (WYFI) 9.26% +0.51, Starfighters Space, Inc. (FJET) 71.88% +0.39, GraniteShares 1.5x Long COIN Daily ETF (CONL) 11.23% +0.38, Outlook Therapeutics Inc (OTLK) 29.93% +0.35, Ocugen (OCGN) 1.23% +0.34, and BioSig Technologies Inc (STEX) 6.85% +0.32.
Ocugen Reports Q1 Revenue of $1.53M, Exceeding Expectations
Reports Q1 revenue $1.53M, consensus $358,140. "In the first few months of 2026, we have completed enrollment of two of our late-stage programs and are diligently working toward initiating our first BLA submission for RP and registration trial for dry AMD later this year," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. "We are executing well against our plans with the highest productivity per employee rate compared to our peers, adequate cash runway with the recent offering, and key milestone achievement to create long-term value creation for our patients and shareholders."
Ocugen Plans to Offer $115M Convertible Senior Notes
Ocugen announced its intention to offer, subject to market conditions and other factors, $115M aggregate principal amount of convertible senior notes due 2034 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。